Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
about
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactionsProstate cancer stem cellsPharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligandsChemistry and structural biology of androgen receptorAdvances in genetics: widening our understanding of prostate cancerResistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate CancerBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentTranslating insights of AR signaling from mouse modelsTargeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceAR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionGlucocorticoids and prostate cancer treatment: friend or foe?Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer.Androgen Receptor-dependent Expression of Low-density Lipoprotein Receptor-related Protein 6 is Necessary for Prostate Cancer Cell Proliferation.Molecular genetics of prostate cancer: new prospects for old challengesImpact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumorsStructural basis for computational screening of non-steroidal androgen receptor ligands.Resistance emerges to second-generation antiandrogens in prostate cancer.Novel drugs targeting the androgen receptor pathway in prostate cancer.In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancerAndrogen receptor signaling and mutations in prostate cancerQuantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Detection of persistent organic pollutants binding modes with androgen receptor ligand binding domain by docking and molecular dynamics.The complex interplay between cholesterol and prostate malignancy.Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsAndrogen receptor signaling in prostate cancer development and progression.Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cellsMechanisms mediating androgen receptor reactivation after castration.Emerging targeted therapies for castration-resistant prostate cancer.Regulation of androgen receptor signaling in prostate cancer.The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.Structure-based virtual screening and identification of a novel androgen receptor antagonist.An update on androgen deprivation therapy for prostate cancer.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Prostate epithelial stem cells.Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.
P2860
Q24532004-D235904B-9D01-47C4-8054-F2B5334338BBQ24654712-48CE2528-9796-4C50-816C-700F5DB2AD00Q24680373-F8E18C36-62DE-4B13-B957-70B8FD0F7AEDQ24685498-9C36F89D-F795-4B77-A4E1-A4C58305CB7FQ26740628-3A1F66BA-D988-4DFE-900B-93CF43703ECFQ26751237-358F053D-A1B1-4113-9EFD-B13D38E3610BQ27007208-1B886043-27B3-4B7C-9E52-3FB4717035C1Q27009424-3219EE84-4111-4ED7-834F-377468E024CFQ27014822-04D195E5-DF2B-4750-8611-743DDEA9AD47Q27675350-227A2813-1D65-4A13-9235-03D79C7D7F37Q28076745-2DF9DEAA-7277-4363-95CF-D4F2F09BC514Q30513836-A9EF1B09-7E11-4975-B0F8-6ABE55C66E20Q33621387-CB6A1676-6B6B-4D8F-8FA6-9AF12EB92CF9Q33728239-8A5417C2-C217-4268-B133-BEB07353B675Q33745234-6D3555C5-949A-4E37-9DC8-4D6041E43A21Q34043947-7E42E33F-E4D5-4DCB-BF1F-4F5DB8D75064Q34127462-FF8DD5AF-7252-49A5-B160-BB0AECF3052EQ34141720-23C510F3-8457-43AD-A3F8-E0D114BC5F7CQ34289773-2AC8E463-FCBA-451B-9A78-D115895F0B2AQ34369873-B4136889-4943-45E2-97C0-71F5F2B3A85EQ34395777-7A9DAFD6-C4A7-4F72-A3EA-59BE38F20D1FQ34424735-D4BDA345-8402-429C-8686-BCE5E78C3E80Q34425907-7C2B6EE8-64DB-44E2-8603-8BA22243B0D8Q34611922-544D9AA2-C1F2-4314-A673-28EF22F2A05CQ34619574-68357974-F65C-4349-82E4-1A56C8444B10Q34993150-796DD7F5-E2F4-453D-B053-9E0C257ECA80Q35137013-B0899BEB-0DD0-4C4D-833C-AD99AC5F299FQ35178389-9091B955-FA1C-4449-9704-D4EEB171AC50Q35183663-4C8DB9CF-FADD-432E-BD72-40BEF35432F2Q35221988-91F456FC-DB37-486C-9D1A-D789BFE235DDQ35633454-854B0634-D815-4ED1-A940-ABF8890F2E7DQ35999255-3F55BFB3-870B-4262-BD7B-D4C70C596DC2Q36066149-67701133-6FCD-4313-9381-BE77823B70E2Q36126914-07050E3D-9F0B-4D5B-A6AC-EA9DA925E879Q36130890-AA7092CF-4BE3-4EAB-8A5B-9E143486C246Q36216496-B0B287C0-3F14-48FE-81A1-A3639C072EB9Q36289952-230BDC1A-9CF9-4595-A19C-869E7F724E27Q36298863-2C9458E4-931C-47AF-90FB-9FFE074FCE6BQ36318592-654A78E4-5ED4-4A6E-B8DD-FE635632B499Q36395111-7D8EA378-8C71-42FA-83E6-C9C7C5AE317C
P2860
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Androgen receptor mutations in ...... d Leukemia Group B Study 9663.
@en
Androgen receptor mutations in ...... d Leukemia Group B Study 9663.
@nl
type
label
Androgen receptor mutations in ...... d Leukemia Group B Study 9663.
@en
Androgen receptor mutations in ...... d Leukemia Group B Study 9663.
@nl
prefLabel
Androgen receptor mutations in ...... d Leukemia Group B Study 9663.
@en
Androgen receptor mutations in ...... d Leukemia Group B Study 9663.
@nl
P2093
P50
P356
P1476
Androgen receptor mutations in ...... nd Leukemia Group B Study 9663
@en
P2093
Barur Rajeshkumar
Bruce A Woda
Cancer and Leukemia Group B Study 9663
Cary P Werner
Daniel F Hayes
Eric J Small
Joel Picus
Nicholas J Vogelzang
Walter Stadler
P304
P356
10.1200/JCO.2003.11.102
P407
P577
2003-07-01T00:00:00Z